Business Context and Reporting Period
This Form 8-K Current Report was filed by Perspective Therapeutics, Inc. (NYSE American: CATX) on January 6, 2025, regarding events occurring on January 2, 2025. The filing primarily addresses a leadership transition within the company's executive management team.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
- Appointment of CFO: The Board appointed Mr. Juan Graham as Chief Financial Officer and principal financial officer, effective January 6, 2025.
- Departure of CFO: Mr. Jonathan Hunt ceased serving as Chief Financial Officer on the effective date but will remain as Chief Accounting Officer and principal accounting officer.
- Compensation Structure: Mr. Graham's employment agreement includes an annual base salary of $500,000, a target annual bonus of 40% of base salary, and a one-time signing bonus of $80,000.
- Equity Grant: Mr. Graham received an option grant for 400,000 shares of common stock, vesting 25% on the first anniversary and monthly thereafter over three years.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding the company's business strategy or market conditions. The primary risk disclosed relates to the repayment of the signing bonus if Mr. Graham voluntarily resigns or is terminated for Cause within two years of employment. Additionally, the agreement outlines specific severance provisions (12 months' salary) in the event of termination without Cause, resignation for Good Reason, or a Change of Control.
Investor Verification Checklist
- Verify the effective date of the CFO transition (January 6, 2025) and the continued role of the former CFO as Chief Accounting Officer.
- Review the full text of the Employment Agreement (to be filed as an exhibit to the 2024 Form 10-K) for detailed definitions of "Cause," "Good Reason," and "Change of Control."
- Confirm the vesting schedule and exercise price of the 400,000 stock options granted to Mr. Graham.
- Monitor future filings for any impact of this leadership change on the company's capital formation and strategic licensing initiatives.